Overview
Orforglipron (LY3502970) is an oral, once-daily, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly (originally discovered by Chugai Pharmaceutical). Unlike injectable peptide GLP-1 agents such as semaglutide or liraglutide, orforglipron is a small molecule taken by mouth with no food or water restrictions, eliminating injection burden. It has completed multiple Phase 3 trials demonstrating significant weight loss and glycemic improvements.
Mechanism of action
Orforglipron acts as a full agonist at the GLP-1 receptor (GLP-1R) through a non-peptide binding mode. It engages the GLP-1R transmembrane domain rather than the extracellular peptide-binding cleft used by native GLP-1 and peptide analogs. Receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying to reduce postprandial glucose excursions, and engages hypothalamic satiety circuits to reduce appetite and caloric intake. Because it is a small molecule, orforglipron is orally bioavailable (~30-40%) and does not require the enteric absorption protections (SNAC excipient, tablet formulation, empty stomach requirements) used by oral semaglutide. CYP3A metabolism supports a half-life of 25-68 hours compatible with once-daily dosing.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| Obesity / weight management (Phase 3 trials) | oral | 12–36 mg | Once daily | Titrated upward in Phase 3 trials to 36 mg once daily. Can be taken without food or water restrictions, unlike oral semaglutide. |
| Type 2 diabetes glycemic control (Phase 3 trials) | oral | 3–36 mg | Once daily | Dose titration from 3 mg upward depending on tolerability. No meal timing restrictions. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
In the ATTAIN-1 Phase 3 trial (72 weeks), orforglipron 36 mg achieved mean weight loss of 12.4% (27.3 lbs) vs 0.9% with placebo. ATTAIN-2 showed 10.5% (22.9 lbs) at 36 mg vs 2.2% placebo. ATTAIN-MAINTAIN showed orforglipron maintained weight loss in patients switching from injectable incretins (semaglutide/tirzepatide). In a head-to-head Phase 3 trial vs oral semaglutide for T2D, orforglipron delivered superior HbA1c reduction and weight loss. Lilly has filed global regulatory submissions for obesity; US diabetes submission in 2026.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Orforglipron for synergistic effects.
Legal status
Investigational new drug; Phase 3 complete, regulatory submissions filed in 2025-2026. Not yet FDA-approved as of April 2026. Expected US regulatory action for obesity in Q2 2026. Not available outside of clinical trials or expanded access programs.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.